Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

16.21 -0.32 (-1.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,742,068
Open 16.74
Bid (Size) 16.10 (71)
Ask (Size) 16.26 (1)
Prev. Close 16.53
Today's Range 16.18 - 16.74
52wk Range 6.150 - 22.11
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Expectations for Catalyst Pharmaceuticals's Future
 
Via Benzinga
4 Analysts Have This to Say About Catalyst Pharmaceuticals
 
Via Benzinga

Performance

YTD
-10.24%
-10.24%
1 Month
+6.30%
+6.30%
3 Month
-12.85%
-12.85%
6 Month
+26.64%
+26.64%
1 Year
+106.50%
+106.50%

More News

Read More
Why Catalyst Pharmaceuticals Shares Are Moving
Via Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Earnings Outlook For Catalyst Pharmaceuticals
Via Benzinga
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Earnings Scheduled For March 15, 2023
Via Benzinga
7 Core Stocks to Build a Solid Portfolio Around
Via InvestorPlace
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
2 Growth Stocks to Invest $1,000 in Right Now
Via The Motley Fool
2 Breakout Growth Stocks to Buy for the Long Haul
Via The Motley Fool
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
7 Smart Stock Picks for Cautious Investors
Via InvestorPlace
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023
Via Benzinga
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
The 7 Best Growth Stocks to Buy for February 2023
Via InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Via The Motley Fool
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
Via Investor's Business Daily
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Via MarketBeat
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.